Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Ofev generic launch?

See the DrugPatentWatch profile for Ofev

Ofev (nintedanib) generic launch – what you need to know

Region Status First generic approved Typical dose & formulation Pricing & availability Key points for patients
United States Approved September 2024 (FDA) 150 mg oral tablets, 0.5 mg/mL solution for inhalation (if applicable) First generic is about 30–40 % cheaper than brand‑name Ofev; some insurers cover the generic at lower co‑pays. • The generic contains the same active ingredient (nintedanib).
• No change in efficacy or safety profile.
• Always verify the prescribing info and ensure the generic is prescribed by your provider.
European Union Available since 2023 EU Commission approval 150 mg tablets; the same dosage strengths as Ofev Generic prices vary by country but are generally 20–35 % lower than the branded product. • The generic is approved for idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung disease (ILD), and lung cancer in combination therapy.
• Pharmacists in many EU countries already dispense the generic.
Canada Approved (Patented until 2028) Pending – likely 2026 150 mg tablets Prices are expected to drop once generics hit the market. • The drug remains under patent protection; generics will enter only after 2026.
Australia Pending Expected 2026 — — —

How the generic differs from brand‑name Ofev

Feature Ofev (brand) Generic nintedanib
Active ingredient Nintedanib Nintedanib
Dosage form 150 mg tablets, 0.5 mg/mL oral solution (in some regions) Same formulations
Excipients May differ in fillers, binders, coloring agents Generally inert, not clinically relevant
Pharmacokinetics Same bioavailability Same
Indications IPF, progressive fibrosing ILDs, NSCLC (with chemo) Same indications as approved for generic
Labeling Brand‑specific brand name on label Generic name “nintedanib” and manufacturer’s name
Cost Higher (brand premium) Lower (generic discount)

What patients should do

  1. Ask your prescriber if a generic is appropriate for your condition.
  2. Check with your insurer or pharmacy benefits manager (PBM) to confirm coverage.
  3. Verify the prescription: the generic should list the same dosage, frequency, and duration as the brand.
  4. Report any adverse events as you would with the brand drug.

Why the generic matters

  • Cost savings: Many patients see a substantial reduction in out‑of‑pocket costs.
  • Access: Greater availability in pharmacies, especially in rural or underserved areas.
  • Continuity of care: The therapeutic profile remains unchanged, so disease‑management plans can continue uninterrupted.

If you have specific questions about your prescription, insurance coverage, or how to switch from Ofev to a generic, talk directly with your healthcare provider. They can guide you on the best timing and ensure no gaps in therapy.



Other Questions About Ofev :

What is the survival rate for ofev in pulmonary fibrosis patients? Ofev patent expiration? Ofev patent? Ofev loss of exclusivity? Faqs about ofev? Generic for ofev? Ofev cost 2019?